Boule Diagnostics (BOUL) Q3 2024 earnings summary

Executive summary

• Q3 2024 sales were SEK 130.4 million, down 6.6% year-over-year, with a 2% organic decline and negative currency effects.

• OEM segment delivered strong growth, with sales up 51%, partially offsetting lower instrument and consumable sales.

• Significant restructuring initiatives underway, expected to yield SEK 16 million in annual savings.

• Major non-cash charges included SEK 265 million impairment on BM900 project and SEK 43 million impairment related to Russian assets.

• Strategic focus on margin expansion, operational excellence, and growth through organic investments and portfolio diversification.

Financial highlights

• Adjusted gross profit increased 6.1% to SEK 61.3 million; adjusted gross margin rose to 47% from 41.4%.

• Adjusted EBIT surged 93.7% to SEK 15.3 million; adjusted operating margin improved to 11.8% from 5.7%.

• Cash flow from operating activities was SEK 5.2 million, down from SEK 27.8 million last year.

• Available liquidity at quarter-end was SEK 48 million, with SEK 31 million in unused credit facilities.

• Equity/assets ratio declined to 47.3% from 61.8% a year ago.

Outlook and guidance

• Manufacturing ramp-up in India on track for Q4 2024, expected to positively impact margins.

• BM950 project performance evaluation scheduled for H1 2025.

• Commercialization of new 5-part system targeted for 2026.

• Investments for Q4 2024 expected at SEK 25 million; full-year 2025 investments to drop to SEK 45 million.

• Long-term targets: operating margin >15%, sales growth >10%, net debt/EBIT <3x.